Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 7, 2017, Pages 1079-1086.e4

  de Vries, Marjan ^a   van Rijckevorsel, Dagmar C M ^a   Vissers, Kris C P ^a   Wilder Smith, Oliver H G ^a,b   van Goor, Harry ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

AE; Chronic Pain; Marijuana; Randomized Controlled Trial

Indexed keywords

11 HYDROXYDRONABINOL; ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; TETRAHYDROCANNABINOL; DRONABINOL;

ABDOMINAL PAIN; ADULT; AMNESIA; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATTENTION DISTURBANCE; BALANCE DISORDER; CHRONIC PAIN; CHRONIC PANCREATITIS; CONFUSION; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EUPHORIA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERHIDROSIS; INCREASED APPETITE; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MIDDLE AGED; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NUMERIC RATING SCALE; PARALLEL DESIGN; PATIENT INFORMATION; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRESCRIPTION; QUALITY OF LIFE; QUESTIONNAIRE; RASH; SCORING SYSTEM; SKIN DISEASE; SLUGGISHNESS; SOMNOLENCE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; VISUAL DISORDER; VISUAL IMPAIRMENT; XEROSTOMIA; AGED; CHEMISTRY; CLINICAL TRIAL; ORAL DRUG ADMINISTRATION; PLASMA; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ABDOMINAL PAIN; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; CHRONIC PAIN; DOUBLE-BLIND METHOD; DRONABINOL; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PLASMA; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85009914373     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.09.147     Document Type: Article

References (39)

1. Drewes, A.M., Krarup, A.L., Detlefsen, S., et al. Pain in chronic pancreatitis: the role of neuropathic pain mechanisms. Gut 57 (2008), 1616–1627.
2. Goulden, M.R., The pain of chronic pancreatitis: a persistent clinical challenge. Br J Pain 7 (2013), 8–22.
3. Dijkstra, F.R., Nieuwenhuijzen, M., Reijnen, M.M., et al. Recent clinical developments in pathophysiology, epidemiology, diagnosis and treatment of intra-abdominal adhesions. Scand J Gastroenterol Suppl 232 (2000), 52–59.
4. Swank, D.J., Swank-Bordewijk, S.C., Hop, W.C., et al. Laparoscopic adhesiolysis in patients with chronic abdominal pain: a blinded randomised controlled multi-centre trial. Lancet 361 (2003), 1247–1251.
5. Attard, J.A., MacLean, A.R., Adhesive small bowel obstruction: epidemiology, biology and prevention. Can J Surg 50 (2007), 291–300.
6. Atsawarungruangkit, A., Pongprasobchai, S., Current understanding of the neuropathophysiology of pain in chronic pancreatitis. World Journal of Gastrointestinal Pathophysiology 6 (2015), 193–202.
7. Latremoliere, A., Woolf, C.J., Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 10 (2009), 895–926.
8. Woolf, C.J., Central sensitization: implications for the diagnosis and treatment of pain. Pain 152:Suppl (2011), S2–S15.
9. Mechoulam, R., Gaoni, Y., Hashish, I.V., the isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 21 (1965), 1223–1229.
10. Pertwee, R.G., Cannabinoid receptors and pain. Prog Neurobiol 63 (2001), 569–611.
11. Eggan, S.M., Lewis, D.A., Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cerebral Cortex 17 (2007), 175–191.
12. Apkarian, A.V., Bushnell, M.C., Treede, R.D., et al. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 9 (2005), 463–484.
13. Hashmi, J.A., Baliki, M.N., Huang, L., et al. Shape shifting pain: chronification of back pain shifts brain representation from nociceptive to emotional circuits. Brain 136:pt 9 (2013), 2751–2768.
14. Lee, M.C., Ploner, M., Wiech, K., et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 154 (2013), 124–134.
15. Walter, C., Oertel, B.G., Felden, L., et al. Brain mapping-based model of delta-tetrahydrocannabinol effects on connectivity in the pain matrix. Neuropsychopharmacology 41 (2016), 1659–1669.
16. Lynch, M.E., Campbell, F., Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. Br J Clin Pharmacol 72 (2011), 735–744.
17. Ben Amar, M., Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 105 (2006), 1–25.
18. Hazekamp, A.G., Grotenhermen, F., Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids 5:special issue (2010), 1–21.
19. ISAP, Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms—prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain 3 (1986), S1–S226.
20. Olesen, A.E., Brokjaer, A., Fisher, I.W., et al. Pharmacological challenges in chronic pancreatitis. World J Gastroenterol 19 (2013), 7302–7307.
21. Ford, A.C., Moayyedi, P., Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 32 (2010), 144–158.
22. Olesen, S.S., Bouwense, S.A., Wilder-Smith, O.H., et al. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology 141 (2011), 536–543.
23. Benedetti, F., Pollo, A., Lopiano, L., et al. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 23 (2003), 4315–4323.
24. Vase, L., Vollert, J., Finnerup, N.B., et al. Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials. Pain 156 (2015), 1795–1802.
25. de Vries, M., van Rijckevorsel, D.C., Wilder-Smith, O.H., et al. Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opin Pharmacother 15 (2014), 1–10.
26. de Vries, M., Van Rijckevorsel, D.C., Vissers, K.C., et al. Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability. Br J Clin Pharmacol 81 (2016), 525–537.
27. Klumpers, L.E., Beumer, T.L., van Hasselt, J.G., et al. Novel delta(9)-tetrahydrocannabinol formulation Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol 74 (2012), 42–53.
28. Schedlowski, M., Enck, P., Rief, W., et al. Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice. Pharmacol Rev 67 (2015), 697–730.
29. Bingel, U., Placebo Competence Team. Avoiding nocebo effects to optimize treatment outcome. JAMA 312 (2014), 693–694.
30. Farrar, J.T., Young, J.P. Jr., LaMoreaux, L., et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 (2001), 149–158.
31. Sullivan, M.J.L., Bishop, S.R., Pivik, J., The Pain Catastrophizing Scale: development and validation. Psychological Assessment 7 (1995), 524–532.
32. Van Damme, S., Crombez, G., Bijttebier, P., et al. A confirmatory factor analysis of the Pain Catastrophizing Scale: invariant factor structure across clinical and non-clinical populations. Pain 96 (2002), 319–324.
33. McCracken, L.M., Zayfert, C., Gross, R.T., The Pain Anxiety Symptoms Scale: development and validation of a scale to measure fear of pain. Pain 50 (1992), 67–73.
34. Bjelland, I., Dahl, A.A., Haug, T.T., et al. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res 52 (2002), 69–77.
35. Ware, J.E. Jr., Sherbourne, C.D., The MOS 36-item short-form health survey (SF-36): I—conceptual framework and item selection. Medical Care 30 (1992), 473–483.
36. Atkinson, M.J., Kumar, R., Cappelleri, J.C., et al. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 8:Suppl 1 (2005), S9–S24.
37. Bond, A., Lader, M., The use of analogue scales in rating subjective feelings. British Journal of Medical Psychology 47 (1974), 211–218.
38. Bowdle, T.A., Radant, A.D., Cowley, D.S., et al. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88 (1998), 82–88.
39. Olesen, S.S., Bouwense, S.A., Wilder-Smith, O.H., et al. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology 141 (2011), 536–543.